Epinephrine intranasal spray - Hikma Pharmaceuticals
Alternative Names: Epinephrine nasal sprayLatest Information Update: 08 Jan 2022
Price :
$50 *
At a glance
- Originator INSYS Therapeutics, Inc
- Developer Hikma Pharmaceuticals
- Class Anti-infectives; Antiallergics; Antiasthmatics; Bronchodilators; Catecholamines; Ethanolamines; Skin disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Beta adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anaphylaxis
Most Recent Events
- 17 Mar 2021 Epinephrine intranasal spray is still in phase II trials for Anaphylaxis (In volunteers) in USA (Intranasal)
- 09 Aug 2019 Hikma Pharmaceuticals acquires epinephrine intranasal spray from Insys Therapeutics
- 09 Jan 2019 INSYS Therapeutics completes a phase-II dose finding pharmacokinetics study for Anaphylaxis (In volunteers) (Intranasal)